Today: 8 June 2026
Browse Category

NYSE:KMB 22 October 2025 - 15 December 2025

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue Stock (KVUE) Today: Latest News, Deal Outlook, Analyst Forecasts and Key Risks (Dec. 15, 2025)

Kenvue shares traded near $17.33 midday Monday, about 7% below the implied $18.59 value of Kimberly-Clark’s pending cash-and-stock offer. The gap reflects market uncertainty as the $48.7 billion deal awaits regulatory and shareholder approval, with closing expected in the second half of 2026. Kimberly-Clark shares stood at $103.15. New legal filings and shareholder law firm activity surfaced Monday.
15 December 2025
··
KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

KVUE Stock Today (Nov. 22, 2025): Kenvue Rises as Kimberly‑Clark Deal, Dividend and Tylenol Ruling Shape Outlook

Kenvue shares closed at $16.64 in late Friday trading, up 3% on heavy volume, but still about 12% below the value implied by Kimberly-Clark’s takeover offer. The deal, announced November 3 and valued at $48–49 billion, would pay Kenvue holders $3.50 in cash plus 0.14625 KMB shares per KVUE share. Both boards approved the merger, expected to close in the second half of 2026.
22 November 2025
·
Kenvue (KVUE) Stock Plunges Amid Tylenol and Talc Fears – What’s Next?

KVUE Stock Today (Nov. 18, 2025): Shares Slip as Appeals Court Weighs Tylenol Cases; Dividend Cleared; Kimberly‑Clark Deal Spread Persists

Kenvue shares traded near $16.13 midday, down 0.7%, after a U.S. appeals court signaled it may revive over 500 Tylenol-autism lawsuits. A Texas judge declined to block Kenvue’s $398 million dividend, which remains set for Nov. 26. The pending Kimberly-Clark deal implies $18.83 per share for KVUE, about 14% above its current price. Volume reached 21.1 million shares by 17:32 UTC.
18 November 2025
·····
Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kenvue (NYSE: KVUE) Stock Surges on $40B Buyout – Spin‑Off Saga, Tylenol Turmoil & Investor Outlook

Kimberly-Clark agreed to acquire Kenvue for $48.7 billion on Nov. 3, 2025, a 46% premium to its prior close. Kenvue shares surged nearly 20% on the news, while Kimberly-Clark stock dropped 13%. The deal follows a turbulent year for Kenvue, including a CEO ouster, falling sales, and litigation over Tylenol safety claims. Kenvue posted $15 billion in 2025 revenue and maintained gross margins near 59%.
4 November 2025
···
Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kenvue (KVUE) Stock Soars 20% on $48.7 B Buyout News – Q3 Earnings Beat and What’s Next

Kimberly-Clark announced a $48.7 billion cash-and-stock deal to acquire Kenvue, sending Kenvue shares up about 20% in pre-market trading to near $17.50. Kenvue shareholders will receive $3.50 in cash and 0.14625 KMB shares per KVUE share. Kenvue reported Q3 net profit of $398 million, beating earnings expectations. Kimberly-Clark shares fell roughly 12.5% on the news.
3 November 2025
····
Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings

Investors Beware: 7 Stocks to Avoid on October 22, 2025 Amid Alarming Warnings

Netflix shares fell over 6% after missing earnings due to a Brazilian tax charge. Texas Instruments warned of weak demand, pushing its stock down 7.6% and dragging chipmakers lower. Target neared multi-year lows as sales dropped and its CEO resigned. The Buffett Indicator hit 219%, with top bankers warning of overvalued markets and possible correction.
22 October 2025
············
1 2 3

Stock Market Today

  • Stock Market Update: Dow Expected to Weaken, Nasdaq to Gain After Sharp Dip; Oil Prices Surge Amid Middle East Conflict
    June 8, 2026, 9:06 AM EDT. The Dow Jones Industrial Average is set to weaken while the Nasdaq Composite is poised for gains after the S&P 500 experienced its worst day since October. This downturn follows renewed violence in the Middle East, with Iran striking Israel, escalating geopolitical tensions. Oil prices jumped significantly, reflecting concerns over supply disruptions linked to the conflict. Investors remain cautious as markets digest the impact of escalating regional instability on global economic outlooks.

Latest articles

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

Plug Power Stock Faces a Make-or-Break Week After Friday’s 10% Drop

8 June 2026
Plug Power rose 2.95% to $3.31 in Monday pre-market trading after a $39.2 million federal tax credit sale tied to its St. Gabriel hydrogen facility, as investors await CEO Jose Luis Crespo’s June 11 update on liquidity and asset sales amid ongoing losses and a recent 10.69% stock drop.
ABAT Shares Jump on DOE’s $115M Lithium Grant Return

ABAT Shares Jump on DOE’s $115M Lithium Grant Return

8 June 2026
American Battery Technology Co shares soared 29.58% to $4.03 premarket after the U.S. Department of Energy fully reinstated a $115 million grant for its Nevada lithium refinery, restoring federal funding for the Tonopah Flats Lithium Project with no change to awarded funds or milestones, though risks remain from permitting, financing, and volatile lithium prices.
NANO Nuclear Stock Bounces, Investors Eye What’s Next

NANO Nuclear Stock Bounces, Investors Eye What’s Next

8 June 2026
NANO Nuclear Energy jumped 7.8% to $25.40 in premarket trading after a 9.9% Friday drop, as traders weighed fresh insider sales filings and recent regulatory progress on its KRONOS microreactor project; the company held $568.7 million in cash as of March 31, but faces sector-wide volatility and execution risks.
Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

Nurix Shares Jump Premarket on Roche $2.3 Billion Cancer Drug Deal

8 June 2026
Nurix soared 20.4% to $17.62 premarket after Roche agreed to pay $700 million up front in a bexobrutideg collaboration worth up to $2.3 billion, a major cash boost and external validation for Nurix’s lead blood cancer drug ahead of a planned Phase 3 trial, with Roche’s clinical and commercial backing now in play.
Go toTop